Analyst initiations 7-24-07: CELL, DFS, MA and X
Posted Jul 24th 2007 11:11AM by Kevin Shult
Filed under: Analyst reports, MasterCard Inc'A' (MA), U.S. Steel (X), Analyst initiations
MOST NOTEWORTHY: Halozyme Therapeutics (HALO), Rosetta Genomics (ROSG), U.S. Steel (X) and BioFuel Energy (BIOF) were today's noteworthy initiations:
- Halozyme (NASDAQ: HALO) was initiated with a Buy rating and $14 target at Oppenheimer. The firm is positive on Halozyme's prospects for signing additional multi-product Enhanze deals in the next 12 months and the company's expanding internal pipeline.
- Oppenheimer also initiated shares of Rosetta Genomics (NASDAQ: ROSG) with a Buy rating and $11 target, as the firm is positive on Rosetta's intellectual property position in the emerging microRNA field related to the development and commercialization of research, diagnostic and therapeutic products, and other applications.
- BioFuel Energy (NASDAQ: BIOF) was initiated with a Neutral rating at Cowen, as the firm sees a lack of catalysts until the company's plants under construction come on line in Q108...
OTHER INITIATIONS:
- Brightpoint (NASDAQ: CELL) was initiated with an Outperform rating and $18 target at Credit Suisse.
- MasterCard (NYSE: MA) was initiated with a Market Perform rating at Wachovia on valuation.
Analyst summaries provided by TheFlyOnTheWall.com (subscription required).Tags: alti, altrair, analyst, biofuel, bopf, brightpoint, cell, dfs, discover, halo, halozyme, initiations, ma, mastercard, rating, rosetta, rosg, sbny, signature, theflyonthewall.com, us steel, UsSteel, x
Related Posts
Is the market always right?
Comfort Zone Investing: How this all might play out
Stock picks and pans for troubled times: AAPL, COST, EWBC, IBM, YUM, PG ...
